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Background. Cardiac disease is a common cause of death
in chronic hemodialysis patients. A subanalysis of the data on
cardiac diseases in the Hemodialysis (HEMO) Study was per-
formed. The specific objectives were: (1) to analyze the preva-
lence of cardiac disease at baseline; (2) to characterize the
incidence of various types of cardiac events during follow-up;
(3) to examine the association of cardiac events during follow-
up with baseline cardiac diseases; and (4) to examine the effect
of dose and flux interventions on various types of cardiac events.
Methods. The HEMO Study is a randomized multi-center
trial on 1846 chronic hemodialysis patients at 15 clinical centers
comprising 72 dialysis units. The scheduled maximum follow-
up duration was 0.9 to 6.6 years, with the mean actual follow-
up of 2.84 years. The interventions were standard-dose versus
high-dose and low-flux versus high-flux hemodialysis in a 2 × 2
factorial design.
Results. At baseline, 80% of patients had cardiac diseases, in-
cluding ischemic heart disease (IHD) (39%), congestive heart
failure (40%), arrhythmia (31%), and other heart diseases
(63%). There were a total of 1685 cardiac hospitalizations, with
angina and acute myocardial infarction accounting for 42.7%
of these hospitalizations. There were 343 cardiac deaths during
follow-up, accounting for 39.4% of all deaths. IHD was impli-
cated in 61.5% of the cardiac deaths. Any cardiac disease at
baseline was highly predictive of cardiac death during follow-
up [relative risk (RR) 2.57; 95% CI 1.73–3.83]. There were no
significant effects of dose or flux assignments on the primary
outcome of all-cause mortality or the main secondary cardiac
composite outcome of first cardiac hospitalization or all-cause
mortality. Assignment to high-flux dialysis was, however, as-
sociated with decreased cardiac mortality and the composite
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outcome of first cardiac hospitalization or death from cardiac
causes.
Conclusion. The HEMO Study identified IHD to be a ma-
jor cause of cardiac hospitalizations and cardiac deaths. Future
strategies for the prevention of cardiac diseases in the main-
tenance hemodialysis population should focus on this entity.
Although high-flux dialysis did not reduce all-cause mortality,
it might improve cardiac outcomes. This hypothesis needs to be
further examined.
Cardiac disease is the leading cause of death among
prevalent maintenance dialysis patients, accounting for
approximately 45% of reported deaths in the United
States [1, 2]. Compared with the general population, dial-
ysis patients have a 10 to 20 times greater incidence of
cardiovascular death [3]. This excess cardiac mortality is,
in part, caused by a high prevalence of cardiac disease
before initiation of dialysis [4, 5], and is likely caused by
the high prevalence of cardiovascular risk factors in pa-
tients with progressive kidney disease [4–6]. In addition,
dialysis patients with cardiac disease have a higher case-
fatality rate than nondialysis patients with heart disease
[7]. These data indicate an urgent need to identify the
types of cardiac diseases, the risk factors for cardiac dis-
ease, and the strategies for prevention and treatment of
cardiac diseases in patients with chronic kidney disease.
Despite the large and growing population of patients
on maintenance hemodialysis in the United States, there
has been a relative lack of large clinical databases de-
scribing the specific cardiac causes of mortality and hos-
pitalization. Most of the available data in this regard
are derived from retrospective analysis of administrative
databases, which is fraught with limitations. In addition,
the contributions of underlying cardiac diseases to subse-
quent cardiac events are unclear. Furthermore, there has
been no large-scale prospective study that evaluated the
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effects of dialysis dose or flux on cardiovascular morbidity
and mortality. The Hemodialysis (HEMO) Study is the
first large-scale prospective clinical trial involving 1846
maintenance hemodialysis patients randomized to either
standard dialysis dose or high dialysis dose and low-flux
or high-flux membranes [10]. In this report, we present
the pre-existing cardiac diseases at baseline in this study,
the incidence of various types of cardiac events during
follow-up, and examine the association of these events
with baseline cardiac diseases. Finally, we report the effi-
cacy of the randomized interventions on specific cardiac
outcomes (death and hospitalizations as a result of car-
diac causes).
METHODS
Study design
The design and methods of the HEMO Study have
been previously reported [8–10]. In brief, the study was
approved by the Institutional Review Board at each of
15 clinical centers associated with 72 participating dialy-
sis units, and all patients gave written informed consent.
The patients were aged 18 to 80 years old, undergoing
in-center hemodialysis thrice weekly, and had been on
dialysis for at least 3 months. Among other exclusion cri-
teria were unstable angina and New York Heart Associa-
tion Class IV congestive heart failure (CHF). Participants
were evaluated during an 8- to 12-week baseline period
between March 1995 and October 2000. They were ex-
cluded from randomization if they were unable to achieve
an equilibrated urea dialysis dose (Kt/V) (eKt/V) [11]
≥1.35 within 4.5 hours, or if their residual kidney urea
clearance was >1.5 mL/min/35 L of urea distribution
volume.
Eligible patients were randomized between May 1995
and February 2001 to either a standard-dose (urea eKt/V
1.05) or high-dose goal (eKt/V 1.45), and to either a low-
flux [mean b 2-microglobulin (b 2M) clearance <10 mL/
min] or a high-flux (mean b 2M clearance >20 mL/
min and ultrafiltration coefficient >14 mL/hr/mm Hg) di-
alyzer in a 2 × 2 factorial design with equal allocation.
The mean achieved eKt/V, single-pool Kt/V (spKt/V),
and urea reduction ratio (URR) during follow-up were
1.16 ± 0.08, 1.32 ± 0.09, and 66.3 ± 2.5%, respectively,
for the standard-dose arm, and 1.53 ± 0.09, 1.71 ± 0.11,
and 75.2 ± 2.5%, respectively, for the high-dose arm. The
mean achieved b 2M clearances were 3.4 ± 7.2 mL/min
and 33.8 ± 11.4 mL/min in the low-flux and high-flux
arms, respectively. The durations of the dialysis sessions
were 190 ± 23, 219 ± 23, 206 ± 28, and 203 ± 27 min-
utes for the standard-dose, high-dose, low-flux, and high-
flux arms, respectively. Standards of general medical care
for blood pressure control, calcium-phosphorus balance,
anemia, and other parameters were monitored by a Qual-
ity of Care Committee. Data collection ended in Decem-
ber 2001. The maximum potential follow-up period for
individual patients was 0.9 to 6.6 years, depending on the
date of randomization.
Collection of baseline cardiac data
During the baseline period, evidence for existing or
history of cardiac disease was collected by study coor-
dinators and investigators using the Index of Disease
Severity (IDS), one of the components of the Index of
Coexisting Disease (ICED) [12]. In addition to the cat-
egories for other diseases, the IDS includes four cate-
gories for cardiac disease: ischemic heart disease (IHD),
CHF, arrhythmias, and other heart diseases. Ascertain-
ment of cardiac disease was accomplished by review of
dialysis unit charts and hospital medical records, with par-
ticular attention paid to electrocardiogram (ECG), chest
x-ray, and echocardiogram reports, which were available
in 82%, 78%, and 41% of patients, respectively. A simple
mention of cardiac disease in these records was sufficient
for coding a diagnosis in the IDS. Each category of car-
diac disease was scored from 0 to 3, with 0 indicating no
disease in that category, and 3 indicating moderate or se-
vere manifestations of the disease, despite treatment. For
this report, we combined all patients with levels of 1 to 3
and classified them as positive for cardiac disease in that
category.
Designation of clinical outcomes
The primary outcome of the HEMO Study was all-
cause mortality. In the design of the study, the main sec-
ondary cardiac outcome was the composite end point of
first cardiac hospitalization or all-cause mortality. Addi-
tional secondary cardiac outcomes included cardiac mor-
tality, the composite of first hospitalization or death from
cardiac disease [10], and hospitalization and deaths from
four specific cardiac causes. The four cardiac causes of
death were: (1) IHD; (2) CHF; (3) arrhythmias, and (4)
other heart diseases. Their subcategories are presented
in Appendix I. Sudden deaths were operationally defined
as witnessed and unwitnessed unexpected deaths, with a
preceding duration of symptoms less than 24 hours for
witnessed deaths, and less than the interval since the last
dialysis session for unwitnessed deaths. Sudden death was
attributed to IHD if the patient had a past history of this
condition, to arrhythmias if the patient had a past history
of arrhythmias in the absence of IHD, and to other heart
diseases if there were other causes of heart disease in the
absence of IHD or arrhythmias.
Hospitalization was attributed to cardiac disease if
it was precipitated or accompanied by any of the fol-
lowing: new onset or worsening angina, myocardial
infarction, CHF, arrhythmias, or other heart diseases. The
category of other heart diseases included hospitalizations
for valvular diseases, pericarditis, and endocarditis. Each
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hospitalization may be attributed to one or more cardiac
cause.
Details of the methods used for the collection and val-
idation of outcome data are presented in Appendix II.
Statistical analyses
Baseline characteristics were summarized by mean and
standard deviations for continuous variables and by rel-
ative frequencies for categorical variables. These charac-
teristics were compared between subgroups by chi-square
tests or by pooled or unpooled t tests as appropriate.
Event rates were computed based on the ratio of the
number of events during the ascertainment period to the
total patient-years before the designated first event or
the end of the ascertainment period. Event rates were
expressed per 100 patient-years by multiplying these ra-
tios by 100.
The relationships of baseline cardiac disease with the
cardiac outcomes were examined by Cox regression
models [14] for each outcome with stratification by the
15 Clinical Centers, and adjusted for the randomized
treatment groups and the following seven prespecified
baseline covariates: age, gender, race, diabetes, years on
dialysis, ICED level computed excluding diabetes, serum
albumin, and for the interaction of serum albumin with
follow-up time [10]. The interaction of baseline albumin
with follow-up time was included in the models to ac-
count for the expectation that the association of baseline
albumin with the cardiac outcomes would decline over
time.
The primary analysis was conducted by Cox regres-
sion of survival after randomization. Effects of random-
ized groups on mortality were tested with stratification by
the Clinical Centers, and adjusted for the following seven
prespecified baseline covariates as described above. Con-
sistent with the calculation of event rates for mortality,
follow-up was censored at the time of renal transplan-
tation, but not transfers. The effects of the randomized
groups on a designated cause of death was analyzed using
the same basic Cox regression model, except that deaths
from causes other than the designated cause were cen-
sored as competing risks. The effects of the randomized
groups on the composite of first cardiac hospitalization
or all-cause death, and on the composite of first cardiac
hospitalization or cardiac death, were analyzed using the
basic Cox model, with transfers censored in addition to
renal transplantation.
The secondary outcome that incorporates cardiac
death and total cardiac hospitalizations include multiple
events in the same patient, and therefore could not be an-
alyzed by the standard Cox regression model. Thus, this
outcome was analyzed using several techniques for multi-
ple events (the Andersen-Gill model, the marginal model
suggested by Wei, Lin, and Weissfeld, the Gaussian frailty
model, and the overdispersed Poisson regression model)
[15]. Because results for comparisons between the flux
arms were consistent among these techniques, only the
results using the overdispersed Poisson regression model
are presented.
Interactions between interventions and baseline car-
diac diseases on outcomes were individually tested using
extensions of the Cox models described above to deter-
mine if the interventions had different effects on cardiac
outcomes in subgroups defined by the various baseline
cardiac conditions.
RESULTS
Baseline characteristics
The demographics and other clinical characteristics of
patients at entry to the study are shown in Table 1. The
study cohort was in general slightly younger and com-
prised more blacks than the dialysis population in the
United States [16]. These patients had been on dialysis
for 3.7 ± 4.4 years before entry into the study, reflect-
ing the exclusion criterion on significant residual kidney
function. There were no differences (P > 0.05) in any of
these variables between the two dose arms or between
the two flux arms, indicating that the patients were well
randomized [10].
Prevalence of cardiac disease at baseline
Cardiac diseases were common at baseline. Eighty per-
cent of the patients had one or more type of cardiac dis-
eases (Fig. 1). There was substantial overlap among the
four specific categories of IHD, CHF, arrhythmia, and
other heart diseases. For example, out of the 725 patients
with IHD, 55% also had CHF, 46% had arrhythmia, and
74% had other heart diseases. Forty-two percent of pa-
tients with CHF also had arrhythmia. Within the category
“other heart diseases,” 46% had left ventricular hypertro-
phy (LVH) by echocardiographic criteria, 52% had LVH
by electrocardiographic criteria, 57% had cardiomegaly
on chest x-ray, 94% had at least one of these three find-
ings that were suggestive of an enlarged heart, 39% had
valvular disease, and 5% had pericarditis. Among the pa-
tients in the “other heart diseases” category, 46% also
had IHD, 50% had CHF, and 38% had arrhythmia.
Differences in baseline cardiac diseases between
demographic subgroups
Any cardiac disease (86.1% vs. 72.8%) and all four cat-
egories of cardiac disease were more (P < 0.0001) preva-
lent in older patients compared to those younger than
58 years. This difference was particularly pronounced
in IHD and arrhythmia, in which the prevalence was
twice as high in the older patients. There were no gen-
der differences in cardiac diseases with the exception of
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Table 1. Baseline characteristics of study cohort
Patients without Patients with P value
pre-existing pre-existing (with vs. without
All patients cardiac disease cardiac disease cardiac
Factors (N = 1846) (N = 367) (N = 1479) disease)e
Age years 57.6 ± 14.0 51.9 ± 15.1 59.0 ± 13.4 0.0001
% Female 56.2 55.9 56.3 0.8727
% Black 62.6 56.7 64.1 0.0085
% Diabetic 44.6 32.7 47.5 <0.0001
ICED levela 2.0 ± 0.8 1.7 ± 0.8 2.1 ± 0.8 0.0001
% with cardiac disease 80.1 0 100 –
Years on dialysis 3.7 ± 4.4 3.9 ± 4.7 3.7 ± 4.3 0.5435
% Residual kidney clearance >0 32.9 35.4 32.3 0.2471
Post-dialysis wt kg 69.2 ± 14.7 69.5 ± 15.2 69.1 ± 14.6 0.6002
Post-dialysis total body total body waterb L 34.9 ± 6.1 35.4 ± 6.4 34.8 ± 6.0 0.1148
Systolic BPc mm Hg 151.8 ± 22.1 149.8 ± 22.8 152.3 ± 22.0 0.0614
Diastolic BPc mm Hg 81.4 ± 13.0 82.9 ± 12.9 81.1 ± 13.0 0.0135
Serum creatininec mg/dL 10.3 ± 2.9 11.1 ± 2.9 10.0 ± 2.8 0.0001
Serum total cholesterol3 mg/dL 172.7 ± 40.7 170.4 ± 39.7 173.2 ± 40.9 0.2426
Serum albuminc g/dL 3.6 ± 0.4 3.7 ± 0.4 3.6 ± 0.4 0.0001
enPCRd g/kg/day 1.03 ± 0.24 1.07 ± 0.23 1.02 ± 0.24 0.0009
Presented are the mean ± SD or percentage.
aIndex of Coexisting Disease (ICED) severity levels computed with diabetes excluded [12].
bPredialysis values. Total body water estimated from anthropometric measurements and demographic data [17].
cPredialysis values.
dEquilibrated normalized protein catabolic rate.
eP values were determined by either chi-square (for categorical variables) or t test (for continuous variable).
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s
An
y c
ard
iac
 di
se
as
e
Isc
he
mi
c h
ea
rt d
ise
as
e
Co
ng
est
ive
 he
art
 fa
ilur
e
Arr
hy
thm
ia
Oth
er 
he
art
 dis
ea
ses
1479
725 733
571
1162
Fig. 1. Various types of cardiac disease at
baseline. The number above each bar de-
notes the number of patients with that spe-
cific type of cardiac disease. There were a to-
tal of 1846 patients in the cohort, implying that
many patients have more than one type of car-
diac disease at baseline. The “other heart dis-
eases” category included 534 patients with left
ventricular hypertrophy on echocardiogram,
604 patients with left ventricular hypertrophy
on electrocardiogram, 664 patients with car-
diomegaly on chest x-ray, 448 patients with
valvular diseases, and 62 patients with peri-
carditis.
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Table 2. Rates of events involving cardiac deaths during follow-up
No. of Rate (per 100
Event events patient-year)
All-cause mortality 871 16.6
1st cardiac hospitalization or 1079 28.5
all-cause mortality
1st cardiac hospitalization or 835 22.0
cardiac death
Cardiac death 343 6.6
Death from ischemic heart disease 211 4.0
Death from congestive heart failure 36 0.7
Death from arrhythmia 59 1.1
Death from other heart diseases 37 0.7
arrhythmia, which was more prevalent (34.7% vs. 28.0%;
P = 0.0023) in males. Blacks had less IHD (36.0% vs.
44.8%; P = 0.0002) and CHF (38.0% vs. 42.6%; P =
0.0490), but more other heart diseases (67.6% vs. 55.2%;
P < 0.0001). Patients with diabetes had higher (P <
0.0030) prevalence of cardiac diseases in all categories
than nondiabetics, with the exception of the other heart
diseases category in which there was no difference. Pa-
tients on dialysis for >3.7 years had more arrhythmia
(36.1% vs. 28.6%; P = 0.0013) and other heart diseases
(69.8% vs. 59.8%; P < 0.0001), but less IHD (35.5% vs.
41.0%; P = 0.0263), compared with those dialyzed for
≤3.7 years.
Classifications and rates of outcomes involving cardiac
deaths during follow-up
Eight outcome measures involving cardiac deaths were
used in the analyses for this report (Table 2). Among
these, all-cause mortality and the composite of first car-
diac hospitalization or all-cause mortality were prespec-
ified outcomes. Additional post-hoc analysis found that
cardiac diseases accounted for 39.4% (343 out of 871)
of all deaths. Among the cardiac deaths, IHD was deter-
mined to be the predominant cause and accounted for
61.5% (211 out of 343). There were 217 sudden deaths;
194 (89.4%) of which were considered to be related to
various cardiac causes. The other 23 were sudden deaths
of unknown causes.
Classifications and rates of cardiac hospitalizations
during follow-up
There were 735 patients who were hospitalized for car-
diac causes during the HEMO Study (Table 3). The total
number of cardiac hospitalizations was 1685. The rates
of first cardiac hospitalization and total cardiac hospital-
ization were 19.4 per 100 patient-years and 34.7 per 100
patient-years, respectively. Approximately 30% of all first
and total cardiac hospitalizations carried more than one
cardiac diagnosis. When angina and myocardial infarc-
tion were combined, this category of IHD accounted for
Table 3. Rates of subcategories of first and total cardiac
hospitalizations
No. of Rate (per 100
hospitalizations patient-year)
First cardiac hospitalizationsa
Any cardiac cause 735 19.4
Angina 247 6.5
Myocardial infarction 127 3.3
Congestive heart failure 283 7.5
Arrhythmia 297 7.8
Other heart diseases 74 2.0
Only 1 cardiac hospitalization 521 13.7
category
>1 cardiac hospitalization 214 5.6
category
Total cardiac hospitalizationsb
Any cardiac cause 1685 34.7
Angina 616 12.7
Myocardial infarction 250 5.2
Congestive heart failure 693 14.3
Arrhythmia 639 13.2
Other heart diseases 174 3.6
Only 1 cardiac hospitalization 1179 24.3
category
>1 cardiac hospitalization 506 10.4
category
aFirst cardiac hospitalization refers to the first time the patient was hospitalized
for the specified cardiac cause during follow-up.
bTotal cardiac hospitalization refers to the total number of hospitalizations
for the specified cardiac cause during follow-up.
42.3% of the first cardiac hospitalizations and 42.7% of
the total cardiac hospitalizations.
Association of baseline cardiac disease burden with
subsequent cardiac events
The association of cardiac diseases at baseline with sub-
sequent cardiac events during follow-up was examined by
Cox regression, after adjustment for baseline age, gender,
race, diabetes, years on dialysis, serum albumin, random-
ized dose arm, and randomized flux arm and stratifica-
tion for Clinical Centers. Any cardiac disease at baseline
was a very strong predictor of all-cause mortality (RR =
1.84) and cardiac death (RR = 2.57), especially death
from IHD (RR = 3.36) and CHF (RR = 6.32) (Table 4).
The presence of IHD, CHF, arrhythmia, or other heart
diseases at baseline was also predictive of subsequent all-
cause mortality and cardiac death. The presence of CHF
or other heart diseases at baseline increased the risk of
death from CHF by 5- to 6-fold. The predictive values of
baseline cardiac disease for cardiac events during follow-
up were in general stronger without adjustment for
covariates.
Effect of randomized dose and flux interventions
on cardiac outcomes based on intent to treat
After adjustment for baseline factors with center strat-
ification, the relative risk for all-cause mortality or any
of the cardiac outcomes associated with the high-dose
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Table 4. Association of baseline cardiac disease with various cardiac events during follow-upa
Cardiac disease at baseline
Any cardiac Ischemic heart Congestive heart Other heart
disease disease failure Arrhythmia diseases
N = 1479 N = 725 N = 733 N = 571 N = 1162
Cardiac event during follow-up No. RRb 95% CIc RR 95%CI RR 95%CI RR 95%CI RR 95%CI
All-cause mortality 871 1.84 1.47–2.29 1.32 1.14–1.53 1.51 1.31–1.74 1.43 1.23–1.65 1.52 1.30–1.79
1st cardiac hosp or ACM 1079 2.20 1.80–2.68 1.47 1.29–1.68 1.58 1.39–1.80 1.33 1.16–1.52 1.64 1.42–1.89
1st cardiac hosp or cardiac death 835 2.33 1.85–2.93 1.66 1.43–1.93 1.62 1.40–1.88 1.26 1.08–1.46 1.63 1.38–1.91
Cardiac death 343 2.57 1.73–3.83 2.02 1.59–2.56 1.65 1.31–2.08 1.44 1.14–1.82 1.67 1.29–2.15
IHD deathd 211 3.36 1.89–5.98 2.82 2.05–3.87 1.40 1.04–1.87 1.42 1.05–1.92 1.49 1.08–2.06
CHF deathe 36 6.32 0.83–48.01 1.71 0.81–3.60 5.05 2.13–11.97 1.75 0.86–3.57 5.95 1.75–20.19
Arrhythmia death 59 1.63 0.72–3.69 1.20 0.69–2.10 1.60 0.92–2.77 1.46 0.84–2.56 1.28 0.71–2.30
Death from other heart diseases 37 1.24 0.52–2.93 0.91 0.42–1.96 1.73 0.86–3.49 1.12 0.53–2.38 1.95 0.88–4.30
aCox regression was performed with adjustment for baseline age, gender, race, diabetes, years on dialysis, serum albumin, randomized Kt/V group, and randomized
flux group, and stratified for center.
bRR, relative risk of developing the cardiac event during follow-up.
c95% CI, 95% confidence interval.
dIHD death, death from ischemia heart disease.
eCHF death, death from congestive heart failure.
Table 5. Effect of randomized dose and flux arms on cardiac outcomes according to intent-to-treat
Randomization to high Kt/V Randomization to high flux
Event No. of events RRa 95% CIb RRa 95% CI
All-cause mortality 871 0.96 0.84–1.10 0.92 0.81–1.05
1st cardiac hosp or ACM 1079 0.99 0.88–1.12 0.90 0.80–1.01
1st cardiac hosp or cardiac death 835 1.00 0.87–1.15 0.87 0.76–1.00
Cardiac death 343 1.03 0.83–1.27 0.80 0.65–0.99
IHD deathc 211 1.03 0.78–1.36 0.89 0.68–1.17
CHF deathd 36 0.82 0.41–1.63 0.65 0.32–1.29
Arrhythmia death 59 1.20 0.71–2.03 0.67 0.40–1.14
Death from other heart diseases 37 1.12 0.58–2.15 0.71 0.36–1.37
Total cardiac hosp or cardiac deathe 1878 1.06 0.90–1.26 0.89 0.75–1.05
aRR, relative risk; risk reduction rate = (1 − RR) × 100%.
b95% CI, 95% confidence interval.
cIHD death, death from ischemic heart disease.
dCHF death, death from congestive heart failure.
eTotal cardiac hospitalization or cardiac death consisted of 1878 total events, which included 735 first cardiac hospitalizations, 827 subsequent cardiac hospitalizations,
and 316 cardiac deaths.
intervention ranged from 0.82 to 1.20 compared with low
dose; none of these comparisons was statistically signifi-
cant (Table 5). The result on all-cause mortality was sim-
ilar without adjustment for baseline factors.
In contrast, the relative risk for all-cause mortality and
all examined cardiac outcomes associated with the high-
flux intervention was consistently below 1.0, although the
reduction was statistically significant (at P < 0.05) for
only two outcome measures (Table 5). Specifically, the
high-flux arm had an 8% (95% CI –5% to 19%) lower
rate of all-cause mortality (primary outcome) and 10%
(−1% to 20%) lower rate of first cardiac hospitalization
or all-cause mortality (main secondary outcome) than the
low-flux arm, but these differences were not statistically
significant. The high-flux arm, however, was associated
with a 20% reduction (95% CI 1% to 35%; P = 0.042)
in cardiac death and a 13% reduction (95% CI 0% to
24%; P = 0.045) in the composite outcome of first cardiac
hospitalization or cardiac death, which were statistically
significant without adjustment for multiple comparisons.
When the specific cardiac causes of death (IHD, CHF,
arrhythmia, and other heart diseases) were analyzed in-
dividually, the high-flux intervention was associated with
a risk reduction in all events, with effect sizes ranging
from 11% to 35%. These decreases were, however, not
statistically significant. High flux was also associated with
a statistically insignificant (11%) decrease in the compos-
ite of total cardiac hospitalization or cardiac death.
The interactions between the presence or absence of
cardiac disease (IHD or any cardiac disease) at base-
line and the randomized interventions (dose or flux) on
six of the eight outcomes listed in Table 3 were exam-
ined. Deaths from CHF and “other heart diseases” were
not examined because of the small number of events in
those categories. The results were adjusted for age, gen-
der, race, diabetes, serum albumin level, and years on
dialysis at baseline. Out of the 24 analyses performed (2
randomized interventions × 2 types of cardiac diseases ×
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6 outcome measures), no strong, consistent effects were
found. These analyses suggest that the presence or ab-
sence of cardiac disease at baseline did not modulate the
effect of dialysis dose or flux on cardiac outcomes.
DISCUSSION
Summary of findings
The results of the present study indicate that (1) the
prevalence of cardiac disease was high (80%) in chronic
hemodialysis patients at baseline; (2) IHD was implicated
in 61.5% of the cardiac deaths in this population; (3) the
presence of any cardiac disease or specific types of car-
diac disease at baseline was a risk factor for all-cause
mortality and cardiac deaths; (4) randomization to the
high-dose arm had no effect on cardiac outcomes. Al-
though randomization to the high-flux arm did not have
any significant benefit on the main secondary composite
outcome of first cardiac hospitalization or all-cause death,
it reduced cardiac deaths and the composite of first car-
diac hospitalization or cardiac death in further analysis.
Baseline prevalence of cardiac disease
The HEMO Study confirms the high prevalence of
IHD, CHF, and arrhythmias in hemodialysis patients [18,
19]. Despite the exclusion of patients with severe CHF
and those with unstable angina, the prevalence of IHD
and CHF (both ∼40%) were higher than those reported
in the United States Renal Data System (USRDS), which
showed prevalence rates of ∼20% for IHD and ∼30%
for CHF [20]. One reason for this difference may be the
different methods of ascertainment of these cardiac con-
ditions. In the HEMO Study, pre-existing cardiac con-
ditions were ascertained using the ICED, based on the
review of medical records by a trained study coordinator.
Previous studies have shown that ICED is more sensi-
tive in capturing the diagnosis of cardiac disease than
the Medical Evidence Report Form 2728 of the Health
Care Finance Administration, which is the basis of the
data reported by the USRDS [20], with similar specificity
[21]. In fact, the 80% prevalence of cardiac disease in the
HEMO Study cohort could still be an underestimation of
the true prevalence because only 41% of the subjects had
cardiac echocardiography performed. Therefore, LVH
might have been missed in some patients.
IHD as main cause of cardiac deaths
Cardiac deaths were common and accounted for 39.4%
of all-cause deaths in the HEMO Study (Table 2). In the
USRDS, cardiac causes account for a moderately higher
fraction (45.2%) of all-cause deaths [1]. More impor-
tantly, 47.2% of the cardiac deaths in the USRDS were
listed as cardiac arrest, while only 27.0% were attributed
to acute myocardial infarction and atherosclerotic heart
disease. In contrast, IHD was implicated in 61.5% of car-
diac deaths in the HEMO Study (Table 2). In addition,
IHD accounted for 42.7% of total cardiac hospitaliza-
tions (Table 3). This substantial difference in outcomes
between the two databases could potentially be a result
of the more careful data collection in the HEMO Study
and differences in death classification. For example, 194
(89.4%) of the 217 sudden deaths were further classified
to be caused by various cardiac causes (e.g., IHD) and
accounted for 56.6% (194/343) of all cardiac deaths. In
the USRDS, these sudden deaths might have been sim-
ply listed as “cardiac arrest, cause unknown” or “cardiac
arrhythmia,” without further classifications. The results
of the death classification in the HEMO Study under-
scores the importance of IHD, and allows a sharper focus
on future preventive strategies to improve the poor car-
diovascular outcomes in maintenance hemodialysis pa-
tients. It should be reckoned that the nature of sudden
deaths in both the HEMO Study and the USRDS has not
been well characterized, and this topic deserves further
investigations.
Baseline cardiac diseases predict cardiac deaths
Any cardiac disease and each specific type of cardiac
diseases at baseline were highly predictive of death from
all causes and from cardiac causes during follow-up. This
type of detailed examination has not been previously re-
ported in the dialysis population. These data suggest that,
while the cardiovascular risk factors might continue or ac-
celerate during the course of maintenance hemodialysis,
the underlying disease burden plays an important role
in determining cardiac mortality in this population. Thus,
interventions to prevent and treat cardiac diseases should
begin early in the course of kidney disease.
Effect of dialysis dose and flux on cardiac outcome
Some [22, 23], but not all [24], of the published ob-
servational studies have reported mortality reductions of
approximately 20% between dose levels similar to the
HEMO high and standard dose arms. The HEMO Study
did not show a significant benefit of high dose in reducing
all-cause mortality or cardiac events (Table 4). This re-
sult was consistent across various cardiac outcomes, with
the average relative risk of the high dose goal compared
with the standard dose goal being close to unity. These
observations suggest that it would be difficult to substan-
tially improve cardiac outcomes through increasing dial-
ysis dose using the thrice-weekly treatment schedule as
currently practiced in the United States. It remains un-
clear, however, if other techniques such as daily or noc-
turnal dialysis would have significant beneficial effects
through additional increases in dialysis dose and fluid
removal.
Our results also did not show any significant benefit of
high-flux dialysis on the main composite cardiac outcome
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(first cardiac hospitalization or all-cause mortality)
(Table 5). However, high flux was associated with statis-
tically significant (at P < 0.05 level) reduction in cardiac
death (20%) and the composite outcome of first cardiac
hospitalization or cardiac death (13%). In patients who
had been on dialysis over 3.7 years before the study, the
risk reduction in cardiac death associated with high flux
was even greater (37%; P =0.016) [25]. These results raise
the possibility that high-flux dialysis may have a benefi-
cial effect on certain cardiac outcomes, especially in pa-
tients on long-term dialysis. A sample size that is larger
than the 1846 patients randomized in the HEMO Study
may be necessary to clearly demonstrate a benefit of
high-flux dialysis on all-cause mortality and other clinical
outcomes. It is also conceivable that b 2-microglobulin
clearances that are substantially greater than that
achieved in the high-flux arm of the HEMO Study (34 mL/
min) [10] and could be achieved through techniques
such as the use of certain types of high-flux dialyzers,
hemodiafiltration, or sorbent technologies would result in
improved cardiac outcomes in a more comprehensive
fashion.
Strengths and limitations
A major strength of this study regarding the preva-
lence of cardiac diseases and the incidence of cardiac
events is that the data were carefully collected by trained
study coordinators and examined by blinded investiga-
tors. Hence, this clinical database is probably more accu-
rate than the national administrative databases that are
often used in other studies. The details that are available
in this database also allow for additional analyses that are
not possible using most administrative databases. Second,
this is the first randomized controlled trial that examined
the effect of dialysis dose and flux on long-term cardiac
outcomes.
There are also several limitations of the present analy-
sis. First, clinical databases tend to be smaller than the
administrative databases, and therefore entail smaller
sample sizes and lower statistical power in general. Sec-
ond, our database is derived from a clinical trial with
its attendant subject exclusion criteria. For example, the
percentage of blacks (62.6%) was higher than those re-
ported in the USRDS. Thus, generalization of these re-
sults to the United States hemodialysis population should
take this caveat into account. Third, because of practical
considerations, the methods used to determine baseline
cardiac disease burden are different from those used to
prospectively determine cardiac events during follow-up.
The fourth limitation relates to the lack of uniform labo-
ratory tests that were required for the diagnosis of cardiac
events in the HEMO Study. For example, serum troponin
levels were not a requirement for the diagnosis of acute
myocardial infarction. However, the Outcome Review
Committee developed written uniform criteria to assign
the primary cause of hospitalization or death, and to ad-
judicate the cardiac events. The fifth limitation relates
to the issue of multiple statistical comparisons of effects
between the randomized interventions; appropriate cau-
tion should therefore be exercised in the interpretation
of results of the additional analyses.
CONCLUSION
Cardiac diseases are major causes of mortality in main-
tenance dialysis patients. Because of the potential of
improving certain cardiac outcomes, the routine use of
high-flux dialysis deserves further investigation. It should
also be acknowledged that neither high-dose dialysis nor
high-flux dialysis, as practiced in the HEMO Study, led
to a large reduction in cardiac events. Alternative or ad-
ditional strategies are needed in order to reduce cardiac
morbidity and mortality in the maintenance hemodialysis
population. In view of the high prevalence of cardiac dis-
eases at baseline, the present study also underscores the
importance of detection and treatment of cardiovascular
diseases at earlier stages of chronic kidney disease.
APPENDIX I. Classifications of cardiac causes of death
1. Ischemic heart disease (IHD)
Sudden death caused by IHD
Acute myocardial infarction
Angina (secondary only∗)
Atherosclerotic heart disease (secondary only∗)
Other acute and subacute forms of IHD
Old myocardial infarction (secondary only∗)
Other forms of chronic IHD (secondary only∗)
2. Congestive heart failure (CHF)
CHF
CHF or pulmonary edema caused by exogenous fluid overload
Cardiogenic pulmonary edema
Cardiogenic shock
3. Arrhythmia and conduction problems
Sudden death caused by arrhythmia, not IHD
Atrioventricular conduction block
Sick sinus syndrome
Atrial fibrillation
Ventricular tachycardia
Other cardiac arrhythmia and conduction disorders
Hyperkalemia
4. Other heart diseases and conditions
Sudden death (caused by heart conditions other than IHD or
arrhythmia)
Pericarditis
Endocarditis (also classified as infectious outcome)
Myocarditis
Pericardial effusion (secondary only∗)
Cardiac tamponade
Aortic valve stenosis or insufficiency (secondary only∗)
Mitral valve stenosis, regurgitation, or prolapse (secondary
only∗)
Other valvular defect (secondary only∗)
Prosthetic valve malfunction (secondary only∗)
Cardiomyopathy (without IHD)
∗“Secondary only” refers to diseases or conditions that could only be
a secondary or contributing cause of death and not the primary cause.
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APPENDIX II. Collection and validation
of outcome data
Procedure of outcome data collection
Each hospitalization or death during follow-up was classified by the
investigator at the Clinical Center using a classification system devised
by the HEMO Study and reported to the Data Coordinating Center.
The data that form the basis for the reports were collected by the Clinical
Center study coordinators and included hospital records, ICD-9 codes,
clinic and dialysis unit notes, diagnostic tests including ECG, echocar-
diograms, other imaging studies, and cardiac catheterization, patient or
family accounts, physician accounts, death certificates, and death noti-
fication forms to the USRDS. Therefore, the coding could be based on
a simple mention in the record alone during baseline, but not during
follow-up. Mandatory comments from the investigator at the Clinical
Center were sent to the Data Coordinating Center for each hospitaliza-
tion or death. A hospitalization event was defined as an overnight stay
in the hospital.
Vital statistics and classification of cause of death were captured on
all 1846 randomized patients by maintaining contact with the dialysis
units to which the patients were transferred. However, resources did not
permit classification of hospitalizations after patients were transferred
to dialysis units not participating in the study. Thus, the definitions of
the ascertainment periods for mortality and hospitalizations differed
slightly. For each patient, the ascertainment period for all-cause mor-
tality and for mortality from specific causes extended from the day of
randomization until (a) renal transplant, (b) death, or (c) the end of
the study on December 31, 2001. The ascertainment period for hospi-
talizations was the day of randomization until either (a), (b), (c), or
(d) transfer to a nonparticipating hemodialysis facility, or to an alter-
native modality of dialysis. A total of 194 patients left the study before
the scheduled end of follow-up because of kidney transplantation, and
198 others transferred to a nonparticipating facility or alternative dial-
ysis modality. The mean durations of the mortality and hospitalization
ascertainment periods were 2.84 and 2.63 years, respectively.
Classification of deaths and quality control
Information from the Clinical Centers regarding deaths and first hos-
pitalizations for cardiac disease or infection was reviewed by the Clinical
Center principal investigator, and an outcome was first adjudicated at
that center. All available information was then sent to the Outcome Re-
view Committee, along with the outcome classification and comments
by the Clinical Center investigators. The Committee was comprised of
investigators from Clinical Centers who were blinded to the arm of ran-
domization for the case under review. Causes of death were classified
into 24 categories, four of which were cardiac causes, as presented in
Appendix I [13].
All death classifications by the Clinical Centers required indepen-
dent audits by two members of the Outcome Review Committee as-
signed by the Data Coordinating Center [13]. Both auditors had access
to the Clinical Center’s diagnosis at the time of the audit. Agreement
on the category of the primary cause of death was required. If either
or both reviewers disagreed with the Clinical Center investigator, the
cause of death was adjudicated during a conference phone call of the
Outcome Review Committee by simple majority vote.
Classification of hospitalizations and quality control
Agreement between the Clinical Center investigator and a member
of the Outcome Review Committee was also required for the classi-
fication of main secondary outcomes, which included first cardiac and
first infectious hospitalizations. When there was disagreement, resolu-
tion was attempted by discussion between these individuals, followed
by adjudication by the full Outcome Review Committee as necessary.
There were a total of 7822 hospitalizations during follow-up. Of these,
1600 were initially identified by the Clinical Center as first cardiac or first
infectious hospitalizations. Of these 1600, 897 were initially classified by
the Clinical Center as hospitalizations due to any cardiac cause, and 305,
147, 355, 353, and 128 were classified as angina, myocardial infarction,
CHF, arrhythmias, and other heart diseases, respectively. The Outcome
Committee review process confirmed 90%, 84%, 93%, 82%, 86%, and
66% of the initial Clinical Center classifications for any cardiac cause,
angina, myocardial infarction, CHF, arrhythmias, and other heart dis-
eases, respectively (correct classification by Clinical Centers). The pro-
portions of the 1600 reviewed hospitalizations that were not identified
by the Clinical Center as caused by a cardiac cause but which were later
classified as cardiac hospitalizations by the Outcome Committee were
3%, and 1%, 1%, 2%, 2%, and 1% for angina, myocardial infarction,
CHF, arrhythmias, and other heart diseases, respectively (false-negative
classification by Clinical Centers).
For quality control purposes, a random sample of approximately 4%
was selected using a computer algorithm from a set of all hospitaliza-
tions excluding those in the previous set of 1600 (i.e., the set that were
not initially identified as a first cardiac or infection hospitalization by the
Clinical Centers). This random sample was generated uniformly over
time from the 15 Clinical Centers from January 31, 1996, to the end of
the Study, resulting in the selection of 279 out of 6222 hospitalizations.
These hospitalizations were then reviewed by the Outcome Committee
using the same process that was used for the 1600 potential first cardiac
or first infection hospitalizations. In this random sample, 91%, 71%,
60%, 100%, 82%, and 50% of the hospitalizations attributed respec-
tively by the Clinical Centers to any cardiac cause, angina, myocardial
infarction, CHF, arrhythmias, and other heart diseases were confirmed
by the Outcome Review Committee (correct classification by Clinical
Centers). The proportions of the hospitalizations in the random sample
of 279 that were not identified by the Clinical Centers but which were
later classified as cardiac hospitalizations by the Outcome Committee
were 4%, 1%, 0%, 2%, 1%, and 1% for any cardiac cause, angina,
myocardial infarction, CHF, arrhythmias, and other heart diseases, re-
spectively (false-negative classification by Clinical Centers).
Overall rates of correct classification and false-negative classifica-
tion by the Clinical Centers for all hospitalizations were obtained by
the appropriately weighed averages of corresponding rates for the 1600
reviewed potential first cardiac or first infectious hospitalizations and
for the random sample of 279. Finally, treating the Outcome Review
classification as the reference standard, the sensitivity and specificity
of the Clinical Center classifications were obtained by applying Bayes’
rule. The sensitivity for the diagnosis of cardiac hospitalization initially
reported by the Clinical Centers was estimated to be 87% for any cardiac
cause, and 90%, 87%, 80%, 86%, and 68% for new onset or worsening
angina, myocardial infarction, CHF, arrhythmia, and other heart dis-
eases, respectively. The specificity was 97% for any cardiac cause, and
98%, 99%, 99%, 99%, and 99% for new onset or worsening angina,
myocardial infarction, CHF, arrhythmia, and other heart diseases,
respectively.
Final ascertainment of outcomes
Outcomes based on classifications of the cause of death and the com-
posite outcomes of first cardiac hospitalization or death and of first
cardiac hospitalization or cardiac death were derived from the final
Outcome Committee classification. However, outcomes defined by spe-
cific causes of cardiac hospitalizations were, in some instances, defined
using the Clinical Center classifications only because the hospitaliza-
tions might not have been initially determined to be first cardiac or
first infectious hospitalizations, and thus were not reviewed by the Out-
come Committee. For example, 356 hospitalizations were designated as
first hospitalizations for angina by the Clinical Center review; of these,
285 were reviewed by the Outcome Committee, but the remaining 71
were not designated for review because they were preceded by another
cardiac hospitalization. Overall, 80%, 73%, 78%, 79%, and 74% of
hospitalizations designated by the Clinical Centers as first angina, first
myocardial infarction, first CHF, first arrhythmia, or first other heart
disease hospitalizations were subsequently reviewed by the Outcome
Committee. Finally, overall rates of cardiac hospitalizations (including
multiple hospitalizations for each patient) were determined entirely
from the Clinical Center classifications because Outcome Committee
review was available for only a small proportion of the total hospital-
izations.
ACKNOWLEDGMENTS
The participation by the patients and the staff in the HEMO Study
is greatly appreciated.
Cheung et al: Cardiac disease in hemodialysis patients 2389
Reprint requests to Alfred K. Cheung, M.D., 85 North Medical Drive
East, University of Utah, Salt Lake City, UT 84112.
E-mail: alfred.cheung@hsc.utah.edu
REFERENCES
1. U.S. RENAL DATA SYSTEM: Cardiovascular special studies, in US-
RDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease
in the United States, Bethesda, MD, National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Diseases,
2002
2. U.S. RENAL DATA SYSTEM: Mortality & causes of death, in USRDS
2002 Annual Data Report: Atlas of End-Stage Renal Disease in the
United States, Bethesda, MD, National Institutes of Health, Na-
tional Institute of Diabetes and Digestive and Kidney Diseases,
2002
3. FOLEY RN, PARFREY PS, SARNAK MJ: Epidemiology of cardiovas-
cular disease in chronic renal disease. J Am Soc Nephrol 9(12
Suppl):S16–23, 1998
4. STACK AG, BLOEMBERGEN WE: Prevalence and clinical correlates of
coronary artery disease among new dialysis patients in the United
States: a cross-sectional study. J Am Soc Nephrol 12:1516–1523, 2001
5. FOLEY RN, PARFREY PS: Cardiac disease in chronic uremia: Clinical
outcome and risk factors. Adv Ren Replace Ther 4:234–248, 1997
6. FUNG F, SHERRARD DJ, GILLEN DL, et al: Increased risk for car-
diovascular mortality among malnourished end-stage renal disease
patients. Am J Kidney Dis 40:307–314, 2002
7. HERZOG CA, MA JZ, COLLINS AJ: Poor long-term survival after
acute myocardial infarction among patients on long-term dialysis.
N Engl Med 339:841–843, 1998
8. EKNOYAN G, LEVEY AS, BECK GJ, et al, FOR THE HEMO STUDY
GROUP: The Hemodialysis (HEMO) Study: Rationale for selection
of interventions. Sem Dialysis 9:24–33, 1996
9. HEMO STUDY GROUP,GREENE T, BECK GJ, et al: Design and statis-
tical issues of the hemodialysis (HEMO) study. Control Clin Trials
21:502–525, 2000
10. EKNOYAN G, BECK GJ, CHEUNG AK, et al, FOR THE HEMO STUDY
GROUP: Effect of dialysis dose and membrane flux on mortality and
morbidity in maintenance hemodialysis patients: Primary results of
the HEMO study. N Engl J Med 347:2010–2019, 2002
11. HEMO STUDY GROUP, DAUGIRDAS JT, DEPNER TA, et al: Compar-
ison of methods to predict equilibrated Kt/V in the HEMO Pilot
Study. Kidney Int 52:1395–1405, 1997
12. MISKULIN DC, ATHIENITES NV, YAN G, et al, FOR THE HEMO STUDY
GROUP: Comorbidity assessment using the index of coexistent dis-
ease in a multicenter clinical trial Study. Kidney Int 60:1498–1510,
2001
13. ROCCO MV, YAN G, GASSMAN J, et al, AND THE HEMO STUDY GROUP:
Comparison of causes of death using HEMO Study and HCFA
end-stage renal disease death notification classification systems. The
National Institutes of Health-funded Hemodialysis. Health Care Fi-
nancing Administration. Am J Kidney Dis 39:146–153, 2002
14. COX DR: Regression models and life tables (with discussion). Series
B. J Royal Statist Soc 34:187–220, 1972
15. THERNEAU TM, GRAMBSCH PM: Modeling Survival Data: Extending
the Cox Model, New York, NY, Springer-Verlag, 2002
16. U.S. RENAL DATA SYSTEM: Incidence and prevalence, in USRDS
2002 Annual Data Report: Atlas of End-Stage Renal Disease in the
United States, Bethesda, MD, National Institutes of Health, Na-
tional Institute of Diabetes and Digestive and Kidney Diseases,
2002
17. WATSON PE, WATSON ID, BATT RD: Total body water volumes for
adult males and females estimated from simple anthropometric
measurements. Am J Clin Nutr 33:27–39, 1980
18. PARFREY PS, FOLEY RN, HARNETT JD, et al: Outcome and risk factors
of ischemic heart disease in chronic uremia. Kidney Int 49:1428–
1434, 1996
19. HARNETT JD, FOLEY RN, KENT GM, et al: Congestive heart failure in
dialysis patients: Prevalence, incidence, prognosis and risk factors.
Kidney Int 47:884–890, 1995
20. U.S. RENAL DATA SYSTEM: USRDS 2000 Annual Data Report,
Bethesda, MD, National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Disease, 2000
21. LONGENECKER JC, CORESH J, KLAG MJ, et al: Validation of comorbid
conditions on the end-stage renal disease medical evidence report:
The CHOICE study (Choices for Healthy Outcomes in Caring for
ESRD). J Am Soc Nephrol 11:520–529, 2000
22. PORT FK, ASHBY VB, DHINGRA RK, et al: Dialysis dose and body
mass index are strongly associated with survival in hemodialysis
patients. J Am Soc Nephrol 13:1061–1066, 2002
23. LI Z, LEW NL, LAZARUS JM, LOWRIE EG: Comparing the urea re-
duction ration and the urea product as outcome-based measures of
hemodialysis dose. Am J Kidney Dis 35:598–605, 2000
24. SHINZATO T, NAKAI S, AKIBA T, et al: Survival in long-term
haemodialysis patients: Results from the annual survey of the
Japanese Society for Dialysis Therapy. Nephrol Dial Transplant
12:884–888, 1997
25. CHEUNG AK, LEVIN NW, GREENE T, et al, FOR THE HEMO STUDY
GROUP: Effect of high flux hemodialysis on clinical outcomes: Re-
sults of the HEMO Study. J Am Soc Nephrol 14:3251–3263, 2003
